Contact Us

SignaBlok, Inc.

Alex Sigalov

SignaBlok, Inc. is a biopharmaceutical company on a fast track to success. Founded in 2009 to develop novel targeted therapeutics and delivery nanosystems through the use of our revolutionary science and technologies, we offer high quality innovation, science and management expertise, encouraging results, an impressive IP portfolio, and growing involvement in international research.

Our pioneering research efforts focus on four core therapeutic areas: cancer, atherosclerosis, inflammatory and immune diseases.

Interested in a proven model for commercializing your science?